Evaluating the safety of traditional medicinal herbs and their major active constituents is critical for their widespread usage.
Geniposide, a major active constituent with a defined structure from the traditional medicinal herb Gardenia jasminoides ELLIS fruit, exhibits remarkable anti-inflammatory, antiapoptotic, and antifibrotic properties and has been used in a variety of medical fields, mainly for the treatment of
liver diseases. However,
geniposide-induced hepatotoxicity and methods for the early detection of hepatotoxicity have yet to be reported. In this study,
geniposide-induced hepatotoxicity was investigated. In addition, candidate
biomarkers for the earlier detection of
geniposide-induced hepatotoxicity were identified using a label-free quantitative proteomics approach on a
geniposide overdose-induced liver injury in a rat model. Using an accurate intensity-based, absolute quantification (iBAQ)-based, one-step discovery and verification approach, a candidate
biomarker panel was easily obtained from individual samples in response to different conditions. To determine the
biomarkers' early detection abilities, five candidate
biomarkers were selected and tested using
enzyme-linked
immunosorbent assays (ELISAs). Two
biomarkers,
glycine N-methyltransferase (GNMT) and
glycogen phosphorylase (PYGL), were found to indicate hepatic
injuries significantly earlier than the current gold standard liver
biomarker. This study provides a first insight into
geniposide-induced hepatotoxicity in a rat model and describes a method for the earlier detection of this hepatotoxicity, facilitating the efficient monitoring of
drug-induced hepatotoxicity.